SKP2 and acute lymphoblastic leukemia: It is noteworthy that in this model of aggressive T-ALL, SKP2 deletion prevented leukemia development in ~30% of mice, which were disease-free for the entire period of the follow-up (>1 year), and delayed onset of leukemia in two thirds of the transplanted cohort.